GRANTS

274 RESULTS

To submit a grant posting, please fill out our web form or download the form so that you can email us at grants@alzforum.org. List the sponsor name, amount, due date, and contact information. This is a free service.

Please Note: We remove grant postings after 6 months. If you would like your listing to be posted longer or taken down sooner, please contact us at grants@alzforum.org.

Clinical Validation of Candidate Biomarkers for Neurological Diseases (U01 Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: April 17, 2018; July 18, 2018; February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Towards Implementing Novel Training Methods to Enhance Cognition in Aging (U01 Clinical Trial Required)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.16 million in FY 2018 to fund three awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: April 30, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Pathway and Target Identification for Alzhiemers Disease Related Dementias (ADRDs) (U01 Clinical Trial Not Allowed)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: NIH intends to fund an estimate of two or three awards, corresponding to $2.5 million in total costs, for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: April 16, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Program to Accelerate Clinical Trials (PACT)

Sponsor: Alzheimer's Drug Discovery Foundation

Award: Up to $3 million based on stage and scope of research. For studies requiring additional support, co-funding from other funding.

Due Date: April 13, 2018. Must be received by 5 p.m. EST on the deadline date.

Prevention Beyond the Pipeline

Sponsor: Alzheimer's Drug Discovery Foundation

Award: Up to $3 million based on stage and scope of research.

Due Date: April 13, 2018. Must be received by 5 p.m. EST on the deadline date.

Drug Discovery

Sponsor: Alzheimer's Drug Discovery Foundation

Award: $150,000-$600,000 based on stage and scope of research.

Due Date: April 13, 2018. Must be received by 5 p.m. EST on the deadline date.

Biomarkers Development

Sponsor: Alzheimer's Drug Discovery Foundation

Award: $150,000-$300,000 based on stage and scope of research.

Due Date: April 13, 2018. Must be received by 5 p.m. EST on the deadline date.

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 - Clinical Trial Optional)

Sponsor: National Institute on Aging, National Cancer Institute

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard due date for resubmission and revision applications is March 16, 2018. The first standard due date for new applications is June 16, 2018.

NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: Applicants should rarely exceed $1 million in total costs per year for a Phase I and $1.5 million in total costs per year for a Phase II/Phase IIB. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization.

Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (U01 Clinical Trial Not Allowed)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: NIH intends to fund an estimated three to four awards, corresponding to $2.5 million in total costs, for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: April 30, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: NINDS and NIA intend to fund one to three awards, corresponding to a total of $3.5 million for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: April 17, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)

Sponsor: National Institute on Aging, National Cancer Institute

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard due date for resubmission and revision applications is March 16, 2018. The first standard due date for new applications is June 16, 2018.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Sponsor: National Institute on Aging, National Institute of Neurological Disorders and Stroke

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: April 17, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Current Filters

No filters selected

Filter By